Federica Di Gregorio

Dr. Federica Di Gregorio


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2024 in Journal of Surgery
Verified
Journal Article
Open access
PDF file
GBGiovanni Barbagallo
Giovanni Barbagallo
FGFederica Di Gregorio
Federica Di Gregorio
Gianluca MonacaGianluca Monaca
Gianluca Monaca
GAGloria Alì
Gloria Alì
VPVanina Porto
Vanina Porto
GAGiovanni Assenza
Giovanni Assenza
Regenerative Reconstructive Treatment of A Peri-Implantitis Case: New Perspectives for Implant Surface Decontamination

15 July 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
FGFederica Di Gregorio
Federica Di Gregorio
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
GMGiorgia Maria Marmo
Giorgia Maria Marmo
AAAngela Angjelova
Angela Angjelova
EJElena Jovanova
Elena Jovanova
Gaetano IsolaGaetano Isola
Gaetano Isola
Background: Recent scientific evidence indicates that the oral–gut axis represents a critical interface in host–microbiota interactions, carrying profound implications for both periodontal and gastrointestinal diseases. This scoping review aims to evaluate the reciprocal influence between periodontitis and inflammatory bowel disease (IBD). Specifically, the underlying mechanisms of microbial translocation, immune interaction, and metabolite-mediated signaling linking the oral microbiota to gut microbial ecology are critically evaluated. Methods: Studies were selected from the PubMed, Web of Science, and Scopus databases up to May 2026. Eligible criteria included in vivo studies written in English and conducted within the last 10 years, whereas human studies involving participants under 18 years of age were excluded. The included studies analyze the effects of oral and gut dysbiosis on the opposing district. Through the database search, 2094 records were identified, and 34 articles were selected based on the eligibility criteria. Results: The included studies demonstrate the interconnection between the oral and gut microbiota. The included studies reveal that predominant oral taxa, specifically Porphyromonas gingivalis, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans, alter intestinal microbial composition. In particular, P. gingivalis colonizes the gut, exacerbating both oral and intestinal inflammation by stimulating pro-inflammatory cytokine expression via Th17 cell activation. Finally, salivary microbial composition appears to be associated with the presence and status of IBD. Conclusions: Understanding these interconnected microbial ecosystems provides valuable insights that may support the future development of integrated diagnostic and therapeutic strategies for patients suffering from periodontitis and IBD. Further large-scale studies with longer follow-up periods are required to standardize potential salivary markers and multidisciplinary therapeutic protocols for the management of periodontitis and IBD.

15 January 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
ATAdriana Antonina Tempesta
Adriana Antonina Tempesta
GAGaia Vertillo Aluisio
Gaia Vertillo Aluisio
FGFederica Di Gregorio
Federica Di Gregorio
RPRoberta Pecora
Roberta Pecora
Maria Lina MezzatestaMaria Lina Mezzatesta
Maria Lina Mezzatesta
MSMaria Santagati
Maria Santagati
Dental caries is a multifactorial chronic infectious disease that impacts healthcare costs globally, caused by alterations of the plaque microbiome and proliferation of cariogenic Streptococcus mutans. Treatments targeting S. mutans, such as alternative strategies using probiotics, might be effective in preventing the development of dental caries. In this study, the probiotic formulation of Lactobacillus reuteri SGL01, vitamin C, and acerola was tested against S. mutans DSM20523. Antimicrobial activity was assessed by deferred antagonism and spot-on-lawn assays for L. reuteri SGL01. MIC and MBC of L. reuteri SGL01 cell-free supernatant (CFS), vitamin C, and acerola were determined with the microdilution method. Time–kill assays determined the bactericidal kinetics for each compound. The checkerboard method was used to evaluate the potential synergistic activity of CFS–vitamin C or CFS–acerola at scalar dilutions from 1 to 8X MIC. Lastly, antibiofilm activity was tested for each compound. Antimicrobial activity of L. reuteri SGL01 was first assessed by classic methods. MIC and MBC values differed for one dilution for all compounds, with values of 25% and 50% for CFS, 9.3 mg/mL and 18.7 mg/mL for vitamin C, and 18.7 mg/mL and 37.5 mg/mL for acerola, respectively. Moreover, time–kill assays confirmed the bactericidal activity at different timepoints: 4 h for CFS, 6 h for vitamin C, and 24 h for acerola. The fractional inhibitory concentration index (FICI) showed indifference for all combinations, and for associations tested at 2, 4, and 8XMIC. S. mutans biofilm production was impaired for all components, with stronger activity by vitamin C and acerola at lower concentrations. The probiotic formulation containing L. reuteri SGl01, vitamin C, and acerola extract exerts a bactericidal effect, especially strong for the CFS, as well as antibiofilm activity. Thus, the combination of these three components could be advantageous for their complementary effects, with use as a novel treatment against the development of dental caries by S. mutans.

8 July 2024
Verified
Book Chapter
Open access
PDF file
GBGiovanni Barbagallo
Giovanni Barbagallo
Gianluca MonacaGianluca Monaca
Gianluca Monaca
FGFederica Di Gregorio
Federica Di Gregorio
GAGloria Alì
Gloria Alì
VPVanina Porto
Vanina Porto
GAGiovanni Assenza
Giovanni Assenza
Probiotics are “live microorganisms that can provide health benefits to the host when ingested in sufficient quantities”. This category of microorganisms includes bacteria and yeasts that are normally present in the human intestine (intestinal microbiota) or similar to them. The introduction of beneficial microorganisms can modulate dysbiotic microbiota, restoring the normal host-microbiota balance. This creates the basis for the use of probiotics as adjunctive treatment in various pathologies such as metabolic diseases, tumors, neurological diseases, and inflammatory bowel diseases. The oral microbiota is a complex and diverse assembly of microorganisms that usually exist in balance with the host. An imbalance in it leads to the development of pathologies, including dental caries and periodontitis. The non-surgical treatment of choice for periodontitis aims at removing hard and soft deposits and disrupting the bacterial biofilm, although periodontal pockets can be immediately recolonized by pathogenic bacteria. The limitations of this therapeutic approach have led to the need for effective adjunctive treatments and support. Studies have shown that adding probiotics as adjuncts in the treatment of periodontitis and peri-implantitis reduces disease indices in both conditions.

Verified
Journal Article
Open access
PDF file
Alessandro PolizziAlessandro Polizzi
Alessandro Polizzi
FGFederica Di Gregorio
Federica Di Gregorio
AAAngela Angjelova
Angela Angjelova
EJElena Jovanova
Elena Jovanova
STSalvatore Torrisi
Salvatore Torrisi
Gaetano IsolaGaetano Isola
Gaetano Isola
Background/Objectives: Oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs) exhibit marked cellular and spatial heterogeneity that is incompletely captured by bulk molecular profiling. This scoping review mapped single-cell and spatial omics applications across oral carcinogenesis and assessed the translational maturity of reported biomarkers and signatures. Methods: MEDLINE via PubMed, Scopus, and Web of Science were searched in August 2026. Human studies of OPMDs and OSCC using eligible single-cell or spatial omics were selected according to a predefined PCC framework and synthesized following JBI and PRISMA-ScR guidance. Biomarkers were classified using a prespecified, review-specific exploratory T0–T4 Translational Maturity Matrix. Results: Of 1405 records identified, 735 duplicates were removed, 670 records screened, and 64 full texts assessed; 55 studies were included. Single-cell RNA sequencing was used in 49/55 studies (89.1%), while 20/55 (36.4%) incorporated spatial omics. Recurrent themes included epithelial plasticity, fibroblast and immune remodeling, spatially organized metabolic and stromal niches, nodal dissemination, and treatment-associated immune reconfiguration. One study was T0, four T1, 27 T2, and 23 T3. T3 reflected validation in an independent patient cohort or external dataset linked to a clinical endpoint, rather than validation of a clinically qualified assay. No study reached T4. Conclusions: Single-cell and spatial omics have refined the oral cancer ecosystem, but clinical translation remains limited by platform heterogeneity, overlapping datasets, and insufficient prospective validation; the maturity framework should therefore be interpreted as an exploratory evidence-mapping tool rather than a validated measure of clinical readiness. Standardized longitudinal studies and clinically deployable assays are needed to advance precision oral oncology.